Teladoc Health Inc News - 4LL

Living Cell Technologies' NTCELL® Continues to Halt Progression of Parkinson's Disease

130 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for...

Living Cell Technologies Group 1 Patients Successfully Treated in Parkinson's Trial

Living Cell Technologies Limited has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL® for...

LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

As advised in our 7 June announcement of the trial results, Dr Barry Snow is presenting 81 week+ data on the safely and clinical effects of...

Living Cell Technologies' NTCELL® Demonstrates Continued Reversal of Parkinson's Disease

81 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for...

LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of...

LCT Completes $2.8M Private Placement and Announces SPP

Living Cell Technologies Limited has completed the placement of 54,607,546 shares at $0.05063 to wholesale investors resident in New...

LCT Receives Ethics Approval for Phase IIb Parkinson's Trial

Living Cell Technologies (ASX: LCT) (OTCQX: LVCLY) has received approval from the Northern A Health and Disability Ethics Committee for the...

NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for...

NTCELL® Clinical Study in Parkinson’s Meets Endpoints

Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying...

LCT and Otsuka of Japan Share Common DIABECELL(R) Vision

LCT and Otsuka of Japan Share Common DIABECELL(R) Vision * Otsuka Pharmaceutical Factory, Inc invests AUD $3 million for 8.2% interest in LCT...

Living Cell Technologies Receives Grant from Juvenile Diabetes Research Foundation International for DIABECELL® NZ Clinical ...

Living Cell Technologies Limited (ASX:LCT) (OTCQX:LVCLY), a global company pioneering the development of a cell implant to...

Report from LCT’s Russian Phase I/IIa Diabetes Trial

Living Cell Technologies Limited (ASX:LCT)(OTCQX:LVCLY), a global company pioneering the development of a cell implant to treat...

Living Cell Technologies Receives Approval to Progress Its Human Phase II Trial of DIABECELL® Treatment for Diabetes to Next...

Living Cell Technologies Limited (ASX:LCT) (OTCQX:LVCLY), a global company pioneering the development of a cell implant to treat...

Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government

SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New...

Living Cell Technologies Announces Collaboration with Centocor Research & Development, Inc.

Living Cell Technologies Limited (ASX:LCT; OTCQX: LVCLY) today announced that the Company has commenced a research agreement with...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Teladoc Health Inc (4LL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

4LL News

Living Cell Technologies' NTCELL® Continues to Halt Progression of Parkinson's Disease

Living Cell Technologies Group 1 Patients Successfully Treated in Parkinson's Trial

LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

Living Cell Technologies' NTCELL® Demonstrates Continued Reversal of Parkinson's Disease

LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

LCT Completes $2.8M Private Placement and Announces SPP

LCT Receives Ethics Approval for Phase IIb Parkinson's Trial

NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

NTCELL® Clinical Study in Parkinson’s Meets Endpoints

LCT and Otsuka of Japan Share Common DIABECELL(R) Vision

Living Cell Technologies Receives Grant from Juvenile Diabetes Research Foundation International for DIABECELL® NZ Clinical ...

Report from LCT’s Russian Phase I/IIa Diabetes Trial

Living Cell Technologies Receives Approval to Progress Its Human Phase II Trial of DIABECELL® Treatment for Diabetes to Next...

Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government

Living Cell Technologies Announces Collaboration with Centocor Research & Development, Inc.

4LL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Teladoc Health Inc (4LL) News

Teladoc Health Inc (4LL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

4LL News

Living Cell Technologies' NTCELL® Continues to Halt Progression of Parkinson's Disease

Living Cell Technologies Group 1 Patients Successfully Treated in Parkinson's Trial

LCT’s NTCELL® Parkinson’s Trial Results to Be Presented in Berlin

Living Cell Technologies' NTCELL® Demonstrates Continued Reversal of Parkinson's Disease

LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson’s Disease

LCT Completes $2.8M Private Placement and Announces SPP

LCT Receives Ethics Approval for Phase IIb Parkinson's Trial

NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

NTCELL® Clinical Study in Parkinson’s Meets Endpoints

LCT and Otsuka of Japan Share Common DIABECELL(R) Vision

Living Cell Technologies Receives Grant from Juvenile Diabetes Research Foundation International for DIABECELL® NZ Clinical ...

Report from LCT’s Russian Phase I/IIa Diabetes Trial

Living Cell Technologies Receives Approval to Progress Its Human Phase II Trial of DIABECELL® Treatment for Diabetes to Next...

Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government

Living Cell Technologies Announces Collaboration with Centocor Research & Development, Inc.

4LL Discussion

Your Recent History